Compassionate use study of caspofungin in children with proven or suspected invasive mycosis or persistent febrile neutropenia.
Madero
L
L
Department of Pediatric Hematology and Oncology, Hospital Infantil Ninõ Jesús, Madrid, Spain. lmadero.hnjs@salud.madrid.org
Sanchez de Toledo
J
J
Castel
V
V
Sevilla
J
J
Gonzalez-Esteban
J
J
Sanz-Rodriguez
C
C
D000293:Adolescent; D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000009:adverse effects*; D000077336:Caspofungin; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000009:adverse effects*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D055666:Lipopeptides; D008297:Male; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology; D009503:Neutropenia / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy / Q000379:methods*; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin; D065819:Voriconazole